When you choose KANJINTI®

AMGEN HELPS YOU TAKE ON MANY ASPECTS OF PATIENT SUPPORT

KANJINTI® (trastuzumab-anns) For Injection
The first and only Herceptin® Biosimilar with SINGLE-TRANSITION study data in the early breast cancer (eBC) setting and the dedicated Amgen level of support2

KANJINTI® is indicated for the treatment of:3

  • HER2-overexpressing breast cancer
  • HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Trastuzumab-anns (KANJINTI®)
is a recommended treatment option
in the NCCN Guidelines®4,†
KANJINTI® sets a rigorous standard
for Herceptin® biosimilarity
The first and only Herceptin® biosimilar with single-transition study data in the eBC setting

The first and only

Herceptin® biosimilar with single-transition study data in the eBC setting

btn-medi_rainbow-svgtotality of evidence

Identical Dosing

to Herceptin® IV

Available in a
Multi-dose‡ 420 mg vial3,5

btn-medi_rainbow-svgdosing
Comprehensive support for you and your patients

The same support you’ve come to expect from AMGEN

Established Q-code: Q5117

btn-medi_rainbow-svgsupport

Backed by
Amgen Expertise

40+

Years

experience in biologics

btn-medi_rainbow-svgbiosimilar expertise
AMGEN® Biosimilars

Get the story behind Amgen's
commitment to biosimilars.

Amgen Biosimilars

*Current as of September 2022.

†NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recognize FDA-approved trastuzumab biosimilars for use in place of trastuzumab (Herceptin®). NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

‡Multi-dose when reconstituted with Bacteriostatic Water for Injection.

HER2 = human epidermal growth factor receptor 2; IV = intravenous; NCCN = National Comprehensive Cancer Network.